Radiopharm extends radioimmunotherapy trial to 5 more cancer types
Radiopharm Theranostics Ltd has received approval to extend its Phase 1 trial of Lu-RAD204 to five more cancer types
GPS
0.00%
4.0¢
GPS ALLIANCE HOLDINGS LIMITED - Announcements
Currently unlisted.
Add to my watchlist
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Announcements
Filter Results
Filters
[Clear]
- Price Sensitive: Yes